Companies › Jiangsu BioJeTay Biotechnology
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Hematology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STSP-0601 for Injection unclear - hemophilia treatment, likely coagulation factor or bypass agent | – | Phase 3 | Hemophilia | Mar 2027 |
| STSA-1301 subcutaneous injection | – | Phase 1 | Primary Immune Thrombocytopenia (ITP) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06929299 | STSA-1301 subcutaneous injection | Phase 1 | Primary Immune Thrombocytopenia (ITP) | Hematology | Sep 2026 |
| NCT06922045 | STSP-0601 for Injection | Phase 3 | Hemophilia | Hematology | Mar 2027 |
No annotated target.
–
Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Shanghai RAAS Blood Products Forma Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.